InvestLog
KLRS Kalaris Therapeutics Inc logo

KLRS Kalaris Therapeutics Inc

Healthcare
$4.92-3.91%ClosedMarket Cap: $92.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.70

P/S

0.00

EV/EBITDA

-1.29

DCF Value

$6.25

FCF Yield

-53.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-72.8%

ROA

-40.2%

ROIC

-46.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-10.9M$—
Q4 null$0.00$-10.0M$—
FY null$0.00$-43.4M$—
Q3 null$0.00$-11.9M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$18.25

Target (Median)

$18.00

Target Range

$14.00 - $23.00

2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
CitizensMarket Outperform
2026-05-13

Trading Activity

Insider Trades

View All
AKKARAJU SRINIVASdirector, 10 percent owner:
BuyFri May 22
AKKARAJU SRINIVASdirector, 10 percent owner:
SellFri May 22
AKKARAJU SRINIVASdirector, 10 percent owner:
SellFri May 22
AKKARAJU SRINIVASdirector, 10 percent owner:
SellFri May 22
Hagen Brett Rofficer: Chief Accounting Officer
SellMon Mar 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.15

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Peers

ARTV logoARTVCNTB logoCNTBCNTX logoCNTXIFRX logoIFRXIMA logoIMAMGX logoMGXOVID logoOVIDQNCX logoQNCXSTRO logoSTROSTTK logoSTTK